 Leverkusen, Germany, Aug. 19, 2020 GLOBE NEWSWIRE -- Biofrontera AG NASDAQ: BFRA; Frankfurt Stock Exchange: B8F the Company, an international biopharmaceutical company, will be releasing its financial results for the first six months ended June 30, 2020 on Wednesday, August 26, 2020. Conference calls for shareholders and interested investors will be held on Thursday, August 27, 2020, at the following times:In German, August 27, 2020 at 10:00 am CEST 4:00 am EST Dial-in number Germany: 49 69201744220 Conference code: 43177738In English, August 27, 2020 at 2:00 pm CEST 8:00 am EST Dial-in number USA: 1 8774230830 Dial-in number UK: 44 2030092470 Conference code: 41610190Please dial in 10 minutes ahead of time to ensure a timely start of the conference call.-End-For enquiries, please contact: Biofrontera AG Thomas Schaffer, Chief Financial Officer 49 0 214 87 63 2 0 IR UK: Seton Services Toni Vallen 44 0 207 229 0805 About Biofrontera:Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics.The Germany-based company, with almost 200 employees worldwide, develops and markets innovative products for the care, protection and treatment of the skin. The companys lead product is the combination of Ameluz, a topical prescription drug, and medical device BF-RhodoLED for the photodynamic therapy of certain superficial skin cancers and their precursors. Ameluz has been marketed in the EU since 2012 and in the United States since May 2016. In addition, the company markets the prescription medication XepiTM for the treatment of impetigo in the United States. In the EU, the company also sells the dermocosmetics series Belixos, which offers specialized care for damaged or diseased skin.Biofrontera is the first German founder-led pharmaceutical company to receive a centralized European and a US approval for a drug developed in-house. The Biofrontera Group was founded in 1997 by the current CEO Prof. Dr. Hermann Lübbert and is listed on the Frankfurt Stock Exchange Prime Standard and on the US NASDAQ. 